Kenya’s Ministry of Health has officially announced plans to introduce Lenacapavir, a new long-acting HIV prevention drug, by January 2026.
Through the National AIDS & STI Control Programme (NASCOP), the ministry confirmed that Kenya is one of only nine early adopter countries selected globally to roll out the innovative medication.
The announcement was made via NASCOP’s official X (Twitter) account on July 14, 2025.
“Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir,” the post read.
Lenacapavir, also known by its brand name Yeztugo, is a World Health Organization (WHO)-approved HIV prevention drug that only requires two injections per year.
It provides an alternative to daily oral pills, making it easier for individuals—especially those in underserved or high-risk populations—to stay protected from HIV.
Health Cabinet Secretary Aden Duale // X (Twitter )
The announcement of Kenya’s adoption of Lenacapavir was made during the IAS 2025 Conference in Kigali, Rwanda, where global health experts hailed it as a major advancement in HIV prevention. Backed by WHO’s recent recommendation, the twice-yearly injectable offers a convenient alternative.
Early trials showed near-total protection, making it a promising tool in reducing infections, particularly among women and adolescents in Africa.
According to health officials, this marks a major step forward in Kenya’s ongoing fight against HIV. With an estimated 1.38 million people living with the virus, the new drug could help reduce new infections significantly, especially among groups such as adolescent girls, young women, and people in remote areas.
While more details on cost, access, and distribution are expected soon, the Ministry says it is working with international partners to make Lenacapavir widely available and affordable.
by bradley odhiambo
